MedTrace Logo

The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)

NCT00403338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2009-10-07

No results posted yet for this study

Summary

1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure on the same diseased area of the coronary artery.

Conditions

  • Coronary Stenosis

Interventions

DEVICE

CYPHER® Bx Velocity™ stent (sirolimus-eluting)

Sponsors & Collaborators

  • Cordis Corporation

    lead INDUSTRY

Principal Investigators

  • Amy Orlick · Cordis Corporation, a Johnson & Johnson Co.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403338 on ClinicalTrials.gov